Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016 (2016), Article ID 3053706, 6 pages
http://dx.doi.org/10.1155/2016/3053706
Review Article

Recent Advances in Treatments of Primary Focal Segmental Glomerulosclerosis in Children

1Department of Pediatrics, Jeju National University School of Medicine, Aran 13gil 15, Jeju-si, Jeju Special Self-Governing Province 63241, Republic of Korea
2Department of Pediatrics, Pusan National University Children’s Hospital, 20 Geumo-ro, Mulgeum-eup, Yangsan-si, Gyeongsangnam-do 50612, Republic of Korea
3Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, 20 Geumo-ro, Mulgeum-eup, Yangsan-si, Gyeongsangnam-do 50612, Republic of Korea

Received 22 December 2015; Revised 21 March 2016; Accepted 30 March 2016

Academic Editor: Jun Oh

Copyright © 2016 Kyoung Hee Han and Seong Heon Kim. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Avner, W. Harmon, P. Niaudet, and N. Yoshikawa, Pediatric Nephrology, vol. 1, Springer, 6th edition, 2009.
  2. A Report of the International Study of Kidney Disease in Children, “The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone,” The Journal of Pediatrics, vol. 98, no. 4, pp. 561–564, 1981. View at Publisher · View at Google Scholar
  3. S. M. Korbet, M. M. Schwartz, and E. J. Lewis, “Primary focal segmental glomerulosclerosis: clinical course and response to therapy,” American Journal of Kidney Diseases, vol. 23, no. 6, pp. 773–783, 1994. View at Publisher · View at Google Scholar · View at Scopus
  4. B. M. Tune, R. Kirpekar, R. K. Sibley, V. M. Reznik, W. R. Griswold, and S. A. Mendoza, “Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up,” Clinical Nephrology, vol. 43, no. 2, pp. 84–88, 1995. View at Google Scholar · View at Scopus
  5. “Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. A report of “Arbetsgemeinschaft für Pädiatrische Nephrologie”,” The Lancet, vol. 1, no. 8113, pp. 401–403, 1979.
  6. S. Samuel, M. Bitzan, M. Zappitelli et al., “Canadian society of nephrology commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: management of nephrotic syndrome in children,” American Journal of Kidney Diseases, vol. 63, no. 3, pp. 354–362, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. J. H. H. Ehrich and J. Brodehl, “Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft fur Padiatrische Nephrologie,” European Journal of Pediatrics, vol. 152, no. 4, pp. 357–361, 1993. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Bagga, P. Hari, and R. N. Srivastava, “Prolonged versus standard prednisolone therapy for initial episode of nephrotic syndrome,” Pediatric Nephrology, vol. 13, no. 9, pp. 824–827, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Ksiazek and T. Wyszynska, “Short versus long initial prednisone treatment in steroid-sensitive nephrotic syndrome in children,” Acta Paediatrica, vol. 84, no. 8, pp. 889–893, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Ueda, M. Chihara, S. Kawaguchi et al., “Intermittent versus long-term tapering prednisolone for initial therapy in children with idiopathic nephrotic syndrome,” The Journal of Pediatrics, vol. 112, no. 1, pp. 122–126, 1988. View at Publisher · View at Google Scholar · View at Scopus
  11. C. B. Sethna and D. S. Gipson, “Treatment of FSGS in children,” Advances in Chronic Kidney Disease, vol. 21, no. 2, pp. 194–199, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Meyrier, “Treatment of primary focal segmental glomerulosclerosis,” Nephrology Dialysis Transplantation, vol. 14, supplement 3, pp. 74–78, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. B. S. Oemar and J. Brodehl, “Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft fur Padiatrische Nephrologie,” Archives of Disease in Childhood, vol. 62, no. 11, pp. 1102–1106, 1987. View at Publisher · View at Google Scholar · View at Scopus
  14. “Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children,” The Lancet, vol. 2, no. 7878, pp. 423–427, 1974.
  15. P. Tarshish, J. N. Tobin, J. Bernstein, and C. M. Edelmann Jr., “Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children,” Pediatric Nephrology, vol. 10, no. 5, pp. 590–593, 1996. View at Publisher · View at Google Scholar · View at Scopus
  16. R. H. White and E. F. Glasgow, “Focal glomerulosclerosis—a progressive lesion associated with steroid-resistant nephrotic syndrome,” Archives of Disease in Childhood, vol. 46, no. 250, pp. 877–878, 1971. View at Google Scholar · View at Scopus
  17. “Chapter 4: steroid-resistant nephrotic syndrome in children,” Kidney International Supplements, vol. 2, no. 2, pp. 172–176, 2012.
  18. D. F. Geary, M. Farine, P. Thorner, and R. Baumal, “Response to cyclophosphamide in steroid-resistant focal segmental glomerulosclerosis: a reappraisal,” Clinical Nephrology, vol. 22, no. 3, pp. 109–113, 1984. View at Google Scholar · View at Scopus
  19. A. Bergstrand, I. Bollgren, A. Samuelsson, T. Törnroth, J. Wasserman, and J. Winberg, “Idiopathic nephrotic syndrome of childhood: cyclophosphamide induced conversion from steroid refractory to highly steroid sensitive disease,” Clinical Nephrology, vol. 1, no. 5, pp. 302–306, 1973. View at Google Scholar · View at Scopus
  20. S. Gulati, S. Pokhariyal, R. K. Sharma et al., “Pulse cyclophosphamide therapy in frequently relapsing nephrotic syndrome,” Nephrology Dialysis Transplantation, vol. 16, no. 10, pp. 2013–2017, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. H. O. Alshaya, J. A. Al-Maghrabi, and J. A. Kari, “Intravenous pulse cyclophosphamide—is it effective in children with steroid-resistant nephrotic syndrome?” Pediatric Nephrology, vol. 18, no. 11, pp. 1143–1146, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. W. P. Rennert, U. K. Kala, D. Jacobs, S. Goetsch, and S. Verhaart, “Pulse cyclophosphamide for steroid-resistant focal segmental glomeruloscleuosis,” Pediatric Nephrology, vol. 13, no. 2, pp. 113–116, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Niaudet and R. Habib, “Cyclosporine in the treatment of idiopathic nephrosis,” Journal of the American Society of Nephrology, vol. 5, no. 4, pp. 1049–1056, 1994. View at Google Scholar · View at Scopus
  24. K. Ishikura, M. Ikeda, S. Hattori et al., “Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial,” Kidney International, vol. 73, no. 10, pp. 1167–1173, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. “Safety and tolerability of cyclosporin A (Sandimmun) in idiopathic nephrotic syndrome. Collaborative Study Group of Sandimmun in Nephrotic Syndrome,” Clinical Nephrology, vol. 35, supplement 1, pp. S48–S60, 1991.
  26. P. Niaudet, “Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone,” The Journal of Pediatrics, vol. 125, no. 6, part 1, pp. 981–986, 1994. View at Publisher · View at Google Scholar · View at Scopus
  27. J. H. H. Ehrich, C. Geerlings, M. Zivicnjak, D. Franke, H. Geerlings, and J. Gellermann, “Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated,” Nephrology Dialysis Transplantation, vol. 22, no. 8, pp. 2183–2193, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Ingulli, A. Singh, N. Baqi, H. Ahmad, S. Moazami, and A. Tejani, “Aggressive, long-term cyclosporine therapy for steroid-resistant focal segmental glomerulosclerosis,” Journal of the American Society of Nephrology, vol. 5, no. 10, pp. 1820–1825, 1995. View at Google Scholar · View at Scopus
  29. D. C. Cattran, G. B. Appel, L. A. Hebert et al., “A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis,” Kidney International, vol. 56, no. 6, pp. 2220–2226, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. A. K. Buscher, B. B. Beck, A. Melk et al., “Rapid response to cyclosporin A and favorable renal outcome in nongenetic versus genetic steroid-resistant nephrotic syndrome,” Clinical Journal of the American Society of Nephrology, vol. 11, no. 2, pp. 245–253, 2016. View at Publisher · View at Google Scholar
  31. A. K. Büscher, B. Kranz, R. Büscher et al., “Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 11, pp. 2075–2084, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Loeffler, M. Gowrishankar, and V. Yiu, “Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome,” Pediatric Nephrology, vol. 19, no. 3, pp. 281–287, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Jahan, R. Prabha, S. Chaturvedi, B. Mathew, D. Fleming, and I. Agarwal, “Clinical efficacy and pharmacokinetics of tacrolimus in children with steroid-resistant nephrotic syndrome,” Pediatric Nephrology, vol. 30, no. 11, pp. 1961–1967, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Gulati, A. Sinha, A. Gupta et al., “Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome,” Kidney International, vol. 82, no. 10, pp. 1130–1135, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Aizawa-Yashiro, K. Tsuruga, S. Watanabe, E. Oki, E. Ito, and H. Tanaka, “Novel multidrug therapy for children with cyclosporine-resistant or -intolerant nephrotic syndrome,” Pediatric Nephrology, vol. 26, no. 8, pp. 1255–1261, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Wu, J. Mao, H. Shen et al., “Triple immunosuppressive therapy in steroid-resistant nephrotic syndrome children with tacrolimus resistance or tacrolimus sensitivity but frequently relapsing,” Nephrology, vol. 20, no. 1, pp. 18–24, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Kim, N. Patnaik, N. Chorny, R. Frank, L. Infante, and C. Sethna, “Second-line immunosuppressive treatment of childhood nephrotic syndrome: a single-center experience,” Nephron Extra, vol. 4, no. 1, pp. 8–17, 2014. View at Publisher · View at Google Scholar
  38. D. S. Gipson, H. Trachtman, F. J. Kaskel et al., “Clinical trial of focal segmental glomerulosclerosis in children and young adults,” Kidney International, vol. 80, no. 8, pp. 868–878, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. J. S. Maltzman and G. A. Koretzky, “Azathioprine: old drug, new actions,” The Journal of Clinical Investigation, vol. 111, no. 8, pp. 1122–1124, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Kusaba, O. Otubo, H. Sugimoto et al., “Immunosuppressive effect of bredinin in the management of patients with renal transplantation,” Proceedings of the European Dialysis and Transplant Association, vol. 18, pp. 420–425, 1981. View at Google Scholar · View at Scopus
  41. M. van Husen and M. J. Kemper, “New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome,” Pediatric Nephrology, vol. 26, no. 6, pp. 881–892, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Imaizumi, Y. Kawasaki, H. Matsuura et al., “Efficacy of steroid pulse, plasmapheresis, and mizoribine in a patient with focal segmental glomerulosclerosis,” Pediatric Nephrology, vol. 22, no. 8, pp. 1215–1218, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. B. Montané, C. Abitbol, J. Chandar, J. Strauss, and G. Zilleruelo, “Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade,” Pediatric Nephrology, vol. 18, no. 8, pp. 772–777, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. N. S. Kumar, A. K. Singh, R. N. Mishra, and J. Prakash, “Comparative study of angiotensin converting enzyme inhibitor and calcium channel blocker in the treatment of steroid-resistant idiopathic nephrotic syndrome,” Journal of Association of Physicians of India, vol. 52, pp. 454–458, 2004. View at Google Scholar · View at Scopus
  45. Z. Yi, Z. Li, X.-C. Wu, Q.-N. He, X.-Q. Dang, and X.-J. He, “Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome,” Pediatric Nephrology, vol. 21, no. 7, pp. 967–972, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. V. J. Savin, E. T. McCarthy, R. Sharma, D. Charba, and M. Sharma, “Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity,” Translational Research, vol. 151, no. 6, pp. 288–292, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Sgambat, M. Banks, and A. Moudgil, “Effect of galactose on glomerular permeability and proteinuria in steroid-resistant nephrotic syndrome,” Pediatric Nephrology, vol. 28, no. 11, pp. 2131–2135, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Kopač, A. Meglič, and R. R. Rus, “Partial remission of resistant nephrotic syndrome after oral galactose therapy,” Therapeutic Apheresis and Dialysis, vol. 15, no. 3, pp. 269–272, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. E. De Smet, J.-P. Rioux, H. Ammann, C. Déziel, and S. Quérin, “FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy,” Nephrology Dialysis Transplantation, vol. 24, no. 9, pp. 2938–2940, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. J. A. Kari, S. M. El-Morshedy, S. El-Desoky, H. O. Alshaya, K. A. Rahim, and B. M. Edrees, “Rituximab for refractory cases of childhood nephrotic syndrome,” Pediatric Nephrology, vol. 26, no. 5, pp. 733–737, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. P. Ravani, A. Bonanni, R. Rossi, G. Caridi, and G. M. Ghiggeri, “Anti-CD20 antibodies for idiopathic nephrotic syndrome in children,” Clinical Journal of the American Society of Nephrology, vol. 11, no. 4, pp. 710–720, 2016. View at Publisher · View at Google Scholar
  52. M. J. Kemper, A. Lehnhardt, A. Zawischa, and J. Oh, “Is rituximab effective in childhood nephrotic syndrome? Yes and no,” Pediatric Nephrology, vol. 29, no. 8, pp. 1305–1311, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. L. Sun, H. Xu, Q. Shen et al., “Efficacy of rituximab therapy in children with refractory nephrotic syndrome: a prospective observational study in Shanghai,” World Journal of Pediatrics, vol. 10, no. 1, pp. 59–63, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. M. D. Pescovitz, B. K. Book, and R. A. Sidner, “Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment,” The New England Journal of Medicine, vol. 354, no. 18, pp. 1961–1963, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Suyama, Y. Kawasaki, K. Miyazaki et al., “Rituximab and low-dose cyclosporine combination therapy for steroid-resistant FSGS,” Pediatrics International, vol. 58, no. 3, pp. 219–223, 2016. View at Publisher · View at Google Scholar
  56. B. Basu, T. K. S. Mahapatra, and N. Mondal, “Mycophenolate mofetil following rituximab in children with steroid-resistant nephrotic syndrome,” Pediatrics, vol. 136, no. 1, pp. e132–e139, 2015. View at Publisher · View at Google Scholar · View at Scopus
  57. H. G. Kang and H. I. Cheong, “Nephrotic syndrome: what’s new, what’s hot?” Korean Journal of Pediatrics, vol. 58, no. 8, pp. 275–282, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. Y. H. Ahn, H. G. Kang, J. M. Lee, H. J. Choi, I.-S. Ha, and H. I. Cheong, “Development of antirituximab antibodies in children with nephrotic syndrome,” Pediatric Nephrology, vol. 29, no. 8, pp. 1461–1464, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. T. Mittal, P. Dedhia, P. Roy-Chaudhury et al., “Complete remission of post-transplantation recurrence of focal segmental glomerulosclerosis with the use of adrenocorticotrophic hormone gel: case report,” Transplantation Proceedings, vol. 47, no. 7, pp. 2219–2222, 2015. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Hogan, A. S. Bomback, K. Mehta et al., “Treatment of idiopathic FSGS with adrenocorticotropic hormone gel,” Clinical Journal of the American Society of Nephrology, vol. 8, no. 12, pp. 2072–2081, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. L. Malaga-Dieguez, D. Bouhassira, D. Gipson, and H. Trachtman, “Novel therapies for FSGS: preclinical and clinical studies,” Advances in Chronic Kidney Disease, vol. 22, no. 2, pp. e1–e6, 2015. View at Publisher · View at Google Scholar · View at Scopus
  62. C.-C. Yu, A. Fornoni, A. Weins et al., “Abatacept in B7-1-positive proteinuric kidney disease,” The New England Journal of Medicine, vol. 369, no. 25, pp. 2416–2423, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. M. S. Joy, D. S. Gipson, L. Powell et al., “Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group,” American Journal of Kidney Diseases, vol. 55, no. 1, pp. 50–60, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. H. Trachtman, F. C. Fervenza, D. S. Gipson et al., “A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis,” Kidney International, vol. 79, no. 11, pp. 1236–1243, 2011. View at Publisher · View at Google Scholar · View at Scopus